MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 200
• Participant gender: Both

Summary

Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse remains an important problem. Therapy options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI), and another transplantation used alone or in combination. However, the efficacy of these interventions is limited. One approach to the relapse problem is to intervene before hematologic or pathologic relapse occurs based on minimal residual disease (MRD). In this study, the efficacy of MRD-directed DLI on transplantation outcomes will be evaluated in patients with acute leukemia receiving allo-HSCT.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborator: Sun Yat-sen University
• Treatments: Cyclosporine; Cyclosporins
• Last Updated: 2016-01-30

Criteria

Inclusion Criteria:

• patients with acute leukemia

• receiving allo-HSCT

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)